Mounjaro FAQ: Approved Uses, Dosing, Cost, and Risks

Mounjaro is the brand name for tirzepatide, a once-weekly injection made by Eli Lilly and sold under New Drug Application 215866, which received its initial U.S. approval in 2022 ^[1][3]. The FDA has approved it for two things: improving blood sugar control, alongside diet and exercise, in adults and children 10 years and older with type 2 diabetes, and lowering the odds of a major cardiovascular event — cardiovascular death, a non-fatal heart attack, or a non-fatal stroke — in adults with type 2 diabetes who face high risk of those events ^[1][4]. Those are the only two indications listed on the label ^[1].

On dosing, the prescribing information sets a starting dose of 2.5 mg injected under the skin once weekly, with increases of 2.5 mg allowed after at least four weeks at a given strength, up to 15 mg weekly for adults and 10 mg weekly for children 10 and older ^[1]. On cost, the list price is $1,112.16 per fill, where one fill means a month’s supply of four pens ^[7]; LillyDirect self-pay pricing starts at $499 per month ^[6]; and eligible commercially insured patients with Mounjaro coverage may pay as little as $25 for a fill through the savings card, subject to caps including $1,950 per calendar year ^[8]. The biggest safety flag is a boxed warning: tirzepatide caused thyroid C-cell tumors in rats, and it is contraindicated for people with certain personal or family histories of medullary thyroid carcinoma or with MEN 2 syndrome ^[1].

What is Mounjaro approved to treat right now?

The label carried at DailyMed, updated August 27, 2026, lists two indications ^[1]. First, Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus ^[1]. Second, it is indicated to reduce the risk of major adverse cardiovascular events — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — in adults with type 2 diabetes mellitus who are at high risk for these events ^[1][4].

Mounjaro is a single molecule that activates two receptors: the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor ^[1][4]. Lilly describes it as the first and only FDA-approved GIP and GLP-1 receptor agonist, and as the #1 prescribed branded type 2 diabetes medicine for adults in the United States ^[4].

The label’s “Recent Major Changes” table shows how recently the approved uses expanded: the pediatric indication for patients 10 and older carries a 12/2025 change date, and the major adverse cardiovascular events indication carries an 08/2026 change date ^[1].

Is Mounjaro approved for weight loss?

No. The label lists exactly two indications: glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes, and reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk ^[1]. No weight-management, obesity, or sleep-apnea indication appears in the label ^[1]. Lilly’s news release about the cardiovascular approval does reference Mounjaro’s “established A1C and weight loss benefits” ^[4], but the approved indications listed in the label remain the two above ^[1].

Can a 10-year-old take Mounjaro, and at what maximum dose?

Yes, patients 10 years and older are included in the approved indication. FDA approved the pediatric expansion on December 19, 2025, under supplement S-039, classified as Efficacy-New Patient Population; the approval letter was signed by John M. Sharretts, M.D., Director of the Division of Diabetes, Lipid Disorders, and Obesity ^[2][3]. The supplemental application had been received on June 20, 2025 ^[2].

The approval was based on trial I8F-MC-GPGV, a randomized, double-blind, placebo-controlled Phase 3 study with an open-label extension, enrolling pediatric and adolescent participants with type 2 diabetes inadequately controlled on metformin, basal insulin, or both ^[2]. That trial fulfilled postmarketing requirement 4271-1 from the May 13, 2022 approval letter, which called for a 30-week placebo-controlled study in patients ages 10 to 17, followed by a 22-week open-label extension ^[2]. The supplied sources describe the trial’s design but not its numeric outcomes, so no results figures appear here ^[2].

The label caps the pediatric dosage at 10 mg subcutaneously once weekly, compared with 15 mg for adults ^[1]. It is not known whether Mounjaro is safe and effective in children under 10 ^[4]. The same supplement also updated warnings sections 5.2 (acute pancreatitis), 5.5 (acute kidney injury), and 5.6 (severe gastrointestinal reactions) to align with labeling for other GLP-1 receptor agonists ^[2].

Does Mounjaro reduce heart attack and stroke risk, and what did SURPASS-CVOT show?

The cardiovascular indication was approved on August 27, 2026, under supplement SUPPL-44, classified as Efficacy-New Indication, and Lilly announced it on August 28, 2026 ^[3][4]. The approval rests on SURPASS-CVOT (NCT04255433), an event-driven, randomized, double-blind, parallel-group Phase 3 trial ^[4].

The trial enrolled 13,299 participants, randomized 1:1 across 640 sites in 30 countries ^[4]. It compared Mounjaro (15 mg or the maximum tolerated dose) against Trulicity (dulaglutide) 1.5 mg, both injected under the skin once weekly, in adults with type 2 diabetes and established atherosclerotic cardiovascular disease ^[4]. Median follow-up ran 210.1 weeks, and the trial lasted roughly five years ^[4].

The result: Mounjaro was non-inferior to dulaglutide for reducing the occurrence of MACE-3, the composite of cardiovascular death, heart attack, or stroke. The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01), which Lilly described as an 8% lower rate of the composite ^[4]. Superiority to dulaglutide was not established ^[4]. Lilly calls SURPASS-CVOT the first cardiovascular outcomes trial to compare two incretin medicines head-to-head rather than against a placebo, and full results were published in The New England Journal of Medicine ^[4]. The most commonly reported adverse events in the trial were gastrointestinal, generally mild-to-moderate, and occurred mainly during dose escalation ^[4].

How is Mounjaro dosed and injected?

All dosing figures here come from the label ^[1]. The recommended starting dosage is 2.5 mg injected subcutaneously once weekly. If additional glycemic control is needed, the dosage may be increased in 2.5 mg increments after at least 4 weeks on the current dose. Maximum dosage is 15 mg subcutaneously once weekly for adults and 10 mg subcutaneously once weekly for pediatric patients 10 years of age and older ^[1].

Mounjaro is administered once weekly at any time of day, with or without meals ^[1]. The injection goes into the abdomen or thigh, or another person can inject the back of the upper arm, and injection sites should be rotated with each dose ^[1]. The label’s Recommended Dosage section (2.1) carries an 08/2026 change date, and the Important Administration Instructions (2.2) carry a 01/2026 date ^[1]. A separate supplement, S-045, approved August 27, 2026, was categorized as Efficacy-New Dosing Regimen ^[3].

Whether a particular dose or schedule suits an individual is a question for a prescriber; this page reports the label, not medical advice.

Which Mounjaro devices and strengths exist?

The label lists two families of presentations ^[1]. Single-dose pens and single-dose vials come in 2.5, 5, 7.5, 10, 12.5, and 15 mg per 0.5 mL ^[1]. Multi-dose vials and single-patient-use KwikPens come in 10 mg/2.4 mL (four 2.5 mg/0.6 mL doses) up to 60 mg/2.4 mL (four 15 mg/0.6 mL doses) ^[1][3].

The multi-dose vial packaging was approved under supplement S-041 on January 7, 2026 ^[3]. The KwikPen was approved January 20, 2026 under supplement S-009, adding six presentations, each holding four once-weekly doses ^[3][5]. That application had a long history: the sNDA was received September 28, 2023, FDA issued an action letter January 29, 2025, and Lilly’s complete response came December 2, 2025 ^[5]. Drugs@FDA also lists Mounjaro (autoinjector) presentations at all six single-dose strengths ^[3].

The label warns, under section 5.10 (added 01/2026), never to share a Mounjaro KwikPen between patients, even if the pen needle is changed ^[1]. For self-pay buyers, the LillyDirect page lists only the single-dose prefilled pen ^[6].

What does Mounjaro cost without insurance, and what do insured patients pay?

The list price, also called the wholesale acquisition cost or WAC, is $1,112.16 per fill, and one fill equals a month’s supply, defined as four pens ^[7]. That WAC figure comes from AnalySource data accessed January 1, 2026 ^[7]. Lilly notes that what patients actually pay at the pharmacy depends on their insurance plan, pharmacy charges, and any discounts or assistance, and that data on specific plan pricing is not yet available ^[7].

For people paying cash, LillyDirect offers self-pay pricing starting at $499 per month, and the same starting figure applies across all six single-dose pen strengths — 2.5, 5, 7.5, 10, 12.5, and 15 mg ^[6]. LillyDirect flags the pens as FSA/HSA eligible, with eligibility varying by plan ^[6]. Terms apply, a prescription is required, and additional taxes and fees may apply ^[6].

For insured patients, the savings card figures below apply. The table puts the main numbers side by side.

Situation	Price or figure	Source
List price (WAC) per fill	$1,112.16	[7]
LillyDirect self-pay, any strength	Starting at $499/month	[6]
Savings card, with commercial coverage	As little as $25 per 1-, 2-, or 3-month fill	[8]
Savings card, commercial insurance without coverage	As low as $499 for a 1-month fill	[8]

How much does the Mounjaro savings card cover?

For commercially insured patients whose plan covers Mounjaro, the card can bring the cost to as little as $25 for a 1-month, 2-month, or 3-month fill ^[8]. Savings are capped at $150 per 1-month fill, $300 per 2-month fill, and $450 per 3-month fill, with a separate annual maximum of $1,950 per calendar year, and the card can be used for up to 13 fills per calendar year ^[8].

For commercially insured patients whose plan does not cover Mounjaro, the card can bring a 1-month fill down to as low as $499, with maximum savings of $647 monthly and $8,411 per calendar year ^[8]. The card expires and savings end on December 31, 2026 ^[8].

The program defines a month as 28 days and up to 4 pens, two months as 56 days and up to 8 pens, and three months as 84 days and up to 12 pens ^[8]. The card is valid only for single-dose pen NDCs (for example 00002-1506-80 and 00002-1495-80); other methods of administration are not eligible ^[8]. The program is not insurance, and Lilly can change or end the terms at any time without notice ^[8].

Who cannot use the savings card, and what about Medicare?

The card excludes anyone enrolled in Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE/CHAMPUS, or any state prescription drug assistance program ^[7][8]. To be eligible otherwise, a person must be prescribed the single-dose pen for an FDA-approved use, be enrolled in commercial drug insurance, live in the United States or Puerto Rico, and be 18 or older ^[8]. Members of alternate funding programs are prohibited from using the card ^[8].

For Medicare beneficiaries, Lilly points to the Medicare Prescription Payment Plan (M3P), a free budgeting tool that spreads prescription drug costs into fixed monthly payments across the plan year; anyone with a Medicare drug plan or Medicare Advantage plan with drug coverage can opt in at any time ^[8]. Questions about how to save on a Mounjaro prescription can go to Lilly Support Services at 1-800-LillyRx (1-800-545-5979) ^[7], and patients without commercial insurance who need assistance may call the Lilly Answers Center at the same number ^[7].

How do I fill a prescription through LillyDirect?

A prescriber sends the prescription to LillyDirect Pharmacy, 1555 S Harding St, Ste 171-B68, Indianapolis, IN 46221, with NPI 1912889320 and NCPDP 1574056 ^[6]. LillyDirect works with four dispensing pharmacies — Amazon Pharmacy, Fuze Health, Gifthealth, and Walmart Pharmacy — and the price is the same regardless of which one fills the order ^[6]. Delivery to the home and retail pickup are both free ^[6].

LillyDirect routinely checks insurance coverage and helps coordinate when prior authorization is required ^[6]. For larger fills, Lilly suggests asking the prescriber about a 3-month prescription, then confirming with the insurance company and pharmacy, since refill timing and plan rules may not allow it ^[8].

What are the serious risks and warnings?

The boxed warning states that tirzepatide causes thyroid C-cell tumors in rats, that it is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, and that the human relevance of the rodent finding has not been determined ^[1]. Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma, in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in anyone with known serious hypersensitivity to tirzepatide or any excipient ^[1]. Symptoms to watch for include a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath ^[4].

Other warnings in the label include: acute pancreatitis, with instructions to discontinue if suspected; hypoglycemia risk when combined with insulin or an insulin secretagogue such as a sulfonylurea, where reducing the dose of those medicines may be necessary; serious hypersensitivity reactions including anaphylaxis and angioedema; acute kidney injury from volume depletion, with monitoring of renal function; severe gastrointestinal reactions, with the drug not recommended in patients with severe gastroparesis; diabetic retinopathy complications in patients with a history of retinopathy, with monitoring for progression (a label change dated 08/2026); acute gallbladder disease, with gallbladder studies indicated if cholelithiasis is suspected; and pulmonary aspiration during general anesthesia or deep sedation, which is why patients should tell providers about planned procedures ^[1][4].

What are the most common side effects and interactions?

The adverse reactions reported in at least 5% of patients treated with Mounjaro are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain ^[1][4]. On interactions, Mounjaro delays gastric emptying and has the potential to affect the absorption of orally administered medications taken alongside it ^[1].

Suspected adverse reactions can be reported to Eli Lilly at 1-800-545-5979 or to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ^[1][4].

How can I tell if Mounjaro is real?

Lilly operates an authenticity-check site at scan.lilly.com that covers both Mounjaro and Zepbound ^[9]. It also publishes guidance on identifying real Lilly medicine and spotting counterfeits at lilly.com/medicines/safety/counterfeit ^[10]. Lilly describes its authorized network — LillyDirect and its four dispensing pharmacies — as the channel supplying authentic Lilly medicines ^[6].

Sources

1. National Library of Medicine. DailyMed. Mounjaro (tirzepatide) injection, solution and Mounjaro KwikPen (tirzepatide) injection, solution.
2. US Food and Drug Administration. Supplement approval letter for Mounjaro (tirzepatide) injection, NDA 215866/S-039.
3. US Food and Drug Administration. Drugs@FDA: New Drug Application 215866, Eli Lilly and Company.
4. Eli Lilly and Company. FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. August 28, 2026.
5. US Food and Drug Administration. Supplement approval letter for Mounjaro KwikPen (tirzepatide) injection, NDA 215866/S-009.
6. Eli Lilly and Company. LillyDirect. Authentic Mounjaro (tirzepatide) shipped to you.
7. Eli Lilly and Company. Mounjaro cost information, with or without insurance.
8. Eli Lilly and Company. Mounjaro (tirzepatide) savings and coverage.
9. Eli Lilly and Company. Check the authenticity of your Zepbound (tirzepatide) and Mounjaro (tirzepatide) medication.
10. Eli Lilly and Company. Identify real Lilly medicine: protect yourself from counterfeit and unsafe, mass compounded products.
11. US Food and Drug Administration. Supplement approval letters for Mounjaro (tirzepatide) injection, NDA 215866/S-044 and S-045.